BUSINESS WIRE; July 13, 1998
The FDA reserves priority review for therapies that would be a significant improvement compared to marketed products in the treatment for a certain disease or condition. The priority review process requires the FDA to review and act on the NDA within six months of the NDA submission date by issuing to the company a complete action letter. The letter may indicate approval or may detail specific deficiencies of the NDA and the actions necessary to place the application in condition for approval.
Ligand submitted the NDA for Panretin gel on May 26, 1998. Panretin gel received orphan drug designation from the FDA in March 1998 for the topical treatment of cutaneous lesions in patients with AIDS-related KS. A drug for diseases or conditions affecting fewer than 200,000 people in the United States is eligible for such designation. Once the product receiving such a designation is approved, it receives seven years of exclusive marketing rights.
"We are very pleased with the FDA's decision to accelerate the review process for Panretin gel," said Ligand chairman, president and chief executive officer David E. Robinson. "Panretin gel, if approved, will be the first topical drug for cutaneous AIDS-related KS. We believe it has the potential to improve the quality of life for patients and will aid physicians in the care, management and treatment of these patients. We are prepared to work closely with the FDA to facilitate their review, and if approved, to make the product available to patients perhaps as soon as the end of this year."
KS is the most frequent AIDS-related malignancy seen in patients and is often characterized by multifocal, widespread lesions at the onset of illness, and may involve the skin, oral mucosa, lymph nodes and visceral organs, such as the lung and gastrointestinal tract. The company estimates that between 30,000 and 50,000 patients in the United States and Western Europe, where Ligand intends to be the primary marketer for Panretin gel, are affected by the disease. A Marketing Authorization Application filing for Europe and a New Drug Submission filing in Canada are currently under preparation for submission this year.
Since 1989, Ligand Pharmaceuticals Incorporated has established a leadership position in gene transcription technology, particularly intracellular receptor (IR) technology and Signal Transducers and Activators of Transcription (STATs). Ligand has applied IR and STATs technology to the discovery and development of small molecule drugs to enhance therapeutic and safety profiles and to address unmet patient needs in cancer, women's and men's health and skin diseases, as well as osteoporosis, metabolic, cardiovascular and inflammatory disease.
This news release may contain certain forward looking statements by Ligand and actual results could differ materially from those described as a result of factors including, but not limited to, the following. There can be no assurance that Panretin gel or any product in the Ligand pipeline, will be successfully developed, that results from more advanced clinical trials will be consistent with earlier results, that drug candidates will show efficacy in all indications currently being studies, that final data will be consistent with interim data, that regulatory approvals will be granted in a timely manner, or at all, that patient physicians acceptance of these products will be achieved, that final results will be supportive of regulatory approvals required to market products.
Ligand undertakes no obligation to update the statements contained in this press release after the date hereof.
Ligand Pharmaceuticals' releases are available via fax at no charge by calling 888/329-9832 or on the world wide web at www.businesswire.com/cnn/lgnd.htm.
CONTACT: Ligand Pharmaceuticals Incorporated Susan Atkins, 619/550-7687 Mary Kenny, 619/550-7536
980713
BW980709
Copyright © 1998 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 1998. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1998. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .